DM
BPMC

Deerfield Management’s Blueprint Medicines BPMC Stock Holding History

Deerfield Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-110,000
Closed -$11.8M – 122
2021
Q4 		$11.8M Sell
110,000
-75,354
-41% -$7.88M 0.25% 78
2021
Q3 		$19.1M Sell
185,354
-96,400
-34% -$8.98M 0.37% 70
2021
Q2 		$24.8M Buy
281,754
+72,754
+35% +$6.67M 0.44% 73
2021
Q1 		$20.3M Buy
+209,000
New +$20.9M 0.43% 73
2020
Q4 		– Sell
-405,386
Closed -$42.7M – 33
2020
Q3 		$37.6M Hold
405,386
– – 0.92% 32
2020
Q2 		$31.6M Sell
405,386
-52,582
-11% -$3.56M 0.92% 35
2020
Q1 		$26.8M Sell
457,968
-106,946
-19% -$6.88M 0.85% 36
2019
Q4 		$45.3M Buy
564,914
+187,714
+50% +$14.1M 1.44% 24
2019
Q3 		$27.7M Sell
377,200
-14,054
-4% -$1.21M 1.13% 28
2019
Q2 		$36.9M Sell
391,254
-115,611
-23% -$9.54M 1.33% 22
2019
Q1 		$40.6M Sell
506,865
-14,135
-3% -$1.04M 1.56% 19
2018
Q4 		$28.1M Sell
521,000
-4,000
-0.8% -$243K 1.12% 34
2018
Q3 		$41M Buy
525,000
+50,050
+11% +$3.48M 1.47% 25
2018
Q2 		$30.1M Buy
474,950
+96,000
+25% +$7.64M 1.06% 39
2018
Q1 		$34.8M Sell
378,950
-17,050
-4% -$1.47M 1.2% 25
2017
Q4 		$29.9M Buy
396,000
+193,000
+95% +$13.6M 1.18% 31
2017
Q3 		$14.1M Hold
203,000
– – 0.64% 51
2017
Q2 		$10.3M Sell
203,000
-1,162,000
-85% -$49.3M 0.55% 53
2017
Q1 		$54.6M Sell
1,365,000
-477,415
-26% -$17.1M 2.11% 10
2016
Q4 		$51.7M Buy
1,842,415
+1,626,829
+755% +$49M 2.13% 14
2016
Q3 		$6.4M Buy
+215,586
New +$5.36M 0.3% 55

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Deerfield Management's BPMC Position: Q1 2022 in Review

Deerfield Management sold out of Blueprint Medicines (BPMC) in Q1 2022, closing a stake of 110,000 shares — an estimated $11.8M sold.

Deerfield Management first reported a position in BPMC in Q3 2016 and held it in 21 quarters. The position peaked at $54.6M in Q1 2017. 248 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • Deerfield Management reported no remaining Blueprint Medicines position as of Q1 2022 after selling out during the quarter.
  • Deerfield Management sold 110,000 Blueprint Medicines shares in Q1 2022, an estimated $11.8M.
  • Deerfield Management first reported a position in Blueprint Medicines in Q3 2016 and held it in 21 quarters.
  • Deerfield Management's Blueprint Medicines position peaked at $54.6M in Q1 2017.
  • 248 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Deerfield Management's 13F filing for Q1 2022, filed 16 May 2022.